ACET
Adicet Bio, Inc.
$8.05
+6.62%
$75.3M
No data for this timeframe.
Vol
Market Cap$75.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders22 funds
Inst. Value$27.5M
Inst. Activity1 buys / 1 sells
Insider Activity3B / 2S
Insider Net $$1.2M
SEC Reports5
Recent Activity
May 20, 2026
SEC
Adicet Bio filed an amended 10-K/A to correct an inadvertent omission in Item 9A — the original filing lacked a statemen
10-K/A — Impact 2/10
May 13, 2026
SEC
Adicet Bio reported Q1 2026 net loss of $20.2M ($1.88/share), narrowing from $28.2M ($4.96/share) YoY, primarily due to
8-K — Impact 4/10
Apr 9, 2026
SEC
OrbiMed Advisors Israel II Ltd, acting on behalf of fund OrbiMed Israel Partners II, L.P., filed a Form 144 to notify in
144 — Impact 3/10
Apr 8, 2026
Insider
ORBIMED ADVISORS LLC sold 32,523 shares
10%+ Owner @ $6.29 ($204.6K)
Apr 7, 2026
Insider
ORBIMED ADVISORS LLC sold 29,319 shares
10%+ Owner @ $6.53 ($191.5K)
Mar 25, 2026
Insider
Aftab Blake was granted 72,555 shares
Chief Scientific Officer
Inst.
Woodline Partners LP — TRIM
313,124 shares ($2.1M)
Inst.
STATE STREET CORP — ADD
36,222 shares ($246.7K)
Price Targets
$34.83
+332.7% upside
Strong Buy
Current $8.05
Low $18.00
Median $22.50
High $100.00
6 analysts
$18.00
$100.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Jan 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 6, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.64 ▲ +28.6% | $-2.19 — $-0.45 | 70% YoY | 4 |
| Next Q | $-1.51 ▲ +35.5% | $-2.37 — $-0.58 | 67% YoY | 4 |
| Current FY | $-8.87 ▲ +9.1% | $-12.19 — $-5.28 | 48% YoY | 6 |
| Next FY | $-4.19 ▼ -2.9% | $-7.01 — $1.34 | 53% YoY | 5 |
Latest Reports
NEUTRAL
10-K/A
2/10
Adicet Bio filed an amended 10-K/A to correct an inadvertent omission in Item 9A — the original filing lacked a statemen
May 20, 2026
NEUTRAL
8-K
4/10
Adicet Bio reported Q1 2026 net loss of $20.2M ($1.88/share), narrowing from $28.2M ($4.96/share) YoY, primarily due to
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $8.1M | — |
| FRANKLIN RESOURCES INC | $4.3M | — |
| CITADEL ADVISORS LLC | $2.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.3M | — |
| Woodline Partners LP | $2.1M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 8, 2026 | ORBIMED ADVISORS | SELL | $204.6K |
| Apr 7, 2026 | ORBIMED ADVISORS | SELL | $191.5K |
| Mar 25, 2026 | Aftab Blake | A | $0.00 |
| Mar 25, 2026 | Healey Don | A | $0.00 |
| Mar 25, 2026 | Maltzman Julia | A | $0.00 |
22 institutional holders with $27.5M total value (4,044,748 shares) as of 2026-Q1. Top holders: RA, FRANKLIN, CITADEL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 1,182,624 | $8.1M | 29.2% | — |
| 2 | FRANKLIN RESOURCES INC | 626,571 | $4.3M | 15.5% | — |
| 3 | CITADEL ADVISORS LLC | 381,823 | $2.6M | 9.4% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 336,524 | $2.3M | 8.3% | — |
| 5 | Woodline Partners LP | 313,124 | $2.1M | 7.7% | TRIM -49.9% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 274,375 | $1.9M | 6.8% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 232,591 | $1.6M | 5.8% | — |
| 8 | Alyeska Investment Group, L.P. | 203,799 | $1.4M | 5.0% | — |
| 9 | Carlyle Group Inc. | 184,295 | $1.3M | 4.6% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 52,900 | $360.2K | 1.3% | — |
| 11 | VANGUARD FIDUCIARY TRUST CO | 50,334 | $342.8K | 1.2% | — |
| 12 | Trexquant Investment LP | 43,666 | $297.4K | 1.1% | — |
| 13 | TWO SIGMA INVESTMENTS, LP | 43,106 | $293.6K | 1.1% | — |
| 14 | BlackRock, Inc. | 36,585 | $249.1K | 0.9% | — |
| 15 | STATE STREET CORP | 36,222 | $246.7K | 0.9% | ADD +39.9% |
| 16 | BARCLAYS PLC | 25,000 | $170.3K | 0.6% | — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 10,778 | $73.4K | 0.3% | — |
| 18 | Vanguard Global Advisers, LLC | 5,221 | $35.6K | 0.1% | — |
| 19 | MORGAN STANLEY | 3,493 | $23.8K | 0.1% | — |
| 20 | ROYAL BANK OF CANADA | 1,699 | $11.0K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Woodline Partners LP | TRIM | 625,000 | 313,124 | -49.9% | $2.1M | 2026-Q1 |
| STATE STREET CORP | ADD | 25,896 | 36,222 | +39.9% | $246.7K | 2026-Q1 |
7 unique insiders with 10 transactions. Net insider value: $1.2M ($1.6M bought, $396.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | SELL | 32,523 | $6.29 | $204.6K |
| Apr 7, 2026 | ORBIMED ADVISORS LLC | 10%+ Owner | SELL | 29,319 | $6.53 | $191.5K |
| Mar 25, 2026 | Aftab Blake | Chief Scientific Officer | AWARD | 72,555 | — | — |
| Mar 25, 2026 | Healey Don | Chief Technology Officer | AWARD | 43,361 | — | — |
| Mar 25, 2026 | Maltzman Julia D. | Chief Medical Officer | AWARD | 72,555 | — | — |
| Mar 25, 2026 | Schor Chen | President & CEO | AWARD | 468,555 | — | — |
| Mar 25, 2026 | Harvey Brian Nicholas | Chief Financial Officer | AWARD | 43,361 | — | — |
| Feb 20, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 74,751 | $7.27 | $543.4K |
| Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 74,268 | $7.21 | $535.5K |
| Feb 18, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | BUY | 74,577 | $7.04 | $525.0K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.2/10.
NEUTRAL
10-K/A
2/10
Adicet Bio filed an amended 10-K/A to correct an inadvertent omission in Item 9A — the original fili
May 20, 2026
NEUTRAL
8-K
4/10
Adicet Bio reported Q1 2026 net loss of $20.2M ($1.88/share), narrowing from $28.2M ($4.96/share) Yo
May 13, 2026
NEUTRAL
144
3/10
OrbiMed Advisors Israel II Ltd, acting on behalf of fund OrbiMed Israel Partners II, L.P., filed a F
Apr 9, 2026
NEUTRAL
144
3/10
OrbiMed Israel GP Ltd., the general partner of OrbiMed Israel Partners Limited Partnership, filed a
Apr 8, 2026
NEUTRAL
EFFECT
4/10
Adicet Bio, Inc. has announced the effectiveness of its shelf registration statement (Form S-3), all
Mar 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.83 mean target
+332.7% upside
Strong Buy (1.00)
$18.00 Low
$100.00 High
| Metric | Value |
|---|---|
| Current Price | $8.05 |
| Target Low | $18.00 |
| Target Mean | $34.83 |
| Target Median | $22.50 |
| Target High | $100.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.64 | $-2.19 | $-0.45 | 69.9% | +28.6% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-1.51 | $-2.37 | $-0.58 | 67.5% | +35.5% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-8.87 | $-12.19 | $-5.28 | 47.7% | +9.1% | 1↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-4.19 | $-7.01 | $1.34 | 52.7% | -2.9% | 1↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.637 | |
| 7d ago | $-1.637 | |
| 30d ago | $-2.292 | +0.655 |
| 60d ago | $-2.160 | +0.523 |
| 90d ago | $-1.805 | +0.167 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 4, 2026
earnings_calendar
ACET Q1 2026 Earnings Scheduled — 2026-05-04
Apr 2, 2026
Clinical Trial
A Phase 1/2 Trial of ADI-270 in ccRCC
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: ADI-270 (Phase 2)
Trial: A Phase 1/2 Trial of ADI-270 in ccRCC
Sponsor: Adicet Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions: Clear Cell Renal
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: ADI-270 (Phase 2)
Trial: A Phase 1/2 Trial of ADI-270 in ccRCC
Sponsor: Adicet Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions: Clear Cell Renal
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: ADI-270 (Phase 2)
Trial: A Phase 1/2 Trial of ADI-270 in ccRCC
Sponsor: Adicet Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions: Clear Cell Renal
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: ADI-270 (Phase 2)
Trial: A Phase 1/2 Trial of ADI-270 in ccRCC
Sponsor: Adicet Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions: Clear Cell Renal
Mar 4, 2026
earnings_calendar
ACET Q4 2025 Earnings After Market Close — 2026-03-04